[go: up one dir, main page]

WO2025007147A3 - Methods for sensitizing drug-resistant cancer cells - Google Patents

Methods for sensitizing drug-resistant cancer cells Download PDF

Info

Publication number
WO2025007147A3
WO2025007147A3 PCT/US2024/036441 US2024036441W WO2025007147A3 WO 2025007147 A3 WO2025007147 A3 WO 2025007147A3 US 2024036441 W US2024036441 W US 2024036441W WO 2025007147 A3 WO2025007147 A3 WO 2025007147A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
cancer cells
resistant cancer
sensitizing drug
sensitizing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/036441
Other languages
French (fr)
Other versions
WO2025007147A2 (en
Inventor
Cigall Kadoch
Claudia Gentile
Katerina Politi
Fernando DE MIGUEL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Dana Farber Cancer Institute Inc
Original Assignee
Yale University
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University, Dana Farber Cancer Institute Inc filed Critical Yale University
Publication of WO2025007147A2 publication Critical patent/WO2025007147A2/en
Publication of WO2025007147A3 publication Critical patent/WO2025007147A3/en
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention is directed to methods of sensitizing tyrosine kinase inhibitor (TKI)-resistant cancer cells in a subject using a SWI/SNF complex modulator.
PCT/US2024/036441 2023-06-30 2024-07-01 Methods for sensitizing drug-resistant cancer cells Pending WO2025007147A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202363524563P 2023-06-30 2023-06-30
US63/524,563 2023-06-30
US202363526676P 2023-07-13 2023-07-13
US63/526,676 2023-07-13

Publications (2)

Publication Number Publication Date
WO2025007147A2 WO2025007147A2 (en) 2025-01-02
WO2025007147A3 true WO2025007147A3 (en) 2025-06-19

Family

ID=93939996

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/036441 Pending WO2025007147A2 (en) 2023-06-30 2024-07-01 Methods for sensitizing drug-resistant cancer cells

Country Status (1)

Country Link
WO (1) WO2025007147A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190269783A1 (en) * 2016-10-21 2019-09-05 Cedars-Sinai Medical Center Compounds and methods to sensitize cancer cells to tyrosine kinase inhibitors
WO2020035779A1 (en) * 2018-08-17 2020-02-20 Novartis Ag Urea compounds and compositions as smarca2/brm atpase inhibitors
US20220218708A1 (en) * 2016-05-27 2022-07-14 The Institute Of Cancer Research:Royal Cancer Hospital Methods for treating smarcb1 deficient cancer or pazopanib resistant cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220218708A1 (en) * 2016-05-27 2022-07-14 The Institute Of Cancer Research:Royal Cancer Hospital Methods for treating smarcb1 deficient cancer or pazopanib resistant cancer
US20190269783A1 (en) * 2016-10-21 2019-09-05 Cedars-Sinai Medical Center Compounds and methods to sensitize cancer cells to tyrosine kinase inhibitors
WO2020035779A1 (en) * 2018-08-17 2020-02-20 Novartis Ag Urea compounds and compositions as smarca2/brm atpase inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LIAO SIDA, DAVOLI TERESA, LENG YUMEI, LI MAMIE Z., XU QIKAI, ELLEDGE STEPHEN J.: "A genetic interaction analysis identifies cancer drivers that modify EGFR dependency", GENES & DEVELOPMENT, vol. 31, no. 2, 15 January 2017 (2017-01-15), US , pages 184 - 196, XP093328145, ISSN: 0890-9369, DOI: 10.1101/gad.291948.116 *
XUE YIBO, MEEHAN BRIAN, FU ZHENG, WANG XUE QING D., FISET PIERRE OLIVIER, RIEKER RALF, LEVINS CAMERON, KONG TIM, ZHU XIANBING, MOR: "SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer", NATURE COMMUNICATIONS, vol. 10, no. 1, 1 January 2019 (2019-01-01), UK, pages 1 - 13, XP093110570, ISSN: 2041-1723, DOI: 10.1038/s41467-019-08380-1 *

Also Published As

Publication number Publication date
WO2025007147A2 (en) 2025-01-02

Similar Documents

Publication Publication Date Title
TR199900048T2 (en) Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
NO20005448L (en) Indole derivatives and their use in the treatment of malignant and other diseases based on pathological cell proliferation
Gross et al. Cytochrome P450 ω-hydroxylase inhibition reduces infarct size during reperfusion via the sarcolemmal KATP channel
DE69506561D1 (en) IMMUNO-CONJUGATES CONTAIN TYROSINE KINASE INHIBITORS
TR200103787T1 (en) Pyrazole compounds useful as inhibitors of extracellular signal regulated kinases (ERK)
ATE482938T1 (en) TYROSINE KINASE INHIBITORS
TR199902923T2 (en) Yumu�ak kas h�cresi�o�almas� olarak (imidazole-5-yl)methyl-2-quinolinone trevleri inhibitor.
CR7074A (en) MERCAPTOACETYLAMIDA DERIVATIVES AND PROCESS FOR PREPARATION AND USE
DK1272188T3 (en) Use of EGFR tyrosine kinase inhibitors for the treatment of breast cancer
EP1304110A3 (en) Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
CL2023003564A1 (en) Bruton tyrosine kinase inhibitors and methods of their use
WO2025007147A3 (en) Methods for sensitizing drug-resistant cancer cells
Hartmann et al. Binaural coherence in rooms
PH12021550857A1 (en) Compounds, compositions, and methods for modulating cdk9 activity
AR123861A1 (en) POLYTHERAPY OF PD-1 AXIS-BINDING ANTAGONISTS AND LRRK2 INHIBITORS
MX2025010157A (en) Preparation method for and use of dihydrothienopyrimidine derivative
WO2023159152A3 (en) Combination therapy of lilrb antagonist and pd-1/pd-l1 axis inhibitor
MX2025001802A (en) Heterocycle rbm39 modulators
MXPA03000089A (en) Use of egf-r protein tyrosine kinase inhibitors for preventing photoaging in human skin.
TR200002203T2 (en) Treatment of follicular lymphomas using inhibitors of the lysophoxin (LT) expression pathway.
EE200300156A (en) Inhibition of tumor cell growth factor dependence
WO2021146506A3 (en) Tyrosine derivatives for modulating cancer
NO20044508L (en) 1- or 3-thiazonaphthoazulenes as inhibitors of tumor necrosis factor production and intermediates for their preparation
WO2023114516A3 (en) Cell-permeant inhibitors of viral cysteine proteases
WO2007016597A3 (en) Targeting tnf-alpha converting enzyme (tace)-dependent growth factor shedding in cancer therapy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24833157

Country of ref document: EP

Kind code of ref document: A2